Enhanced incorporation of 1-beta-D-arabinofuranosylcytosine by pretreatment with etoposide. 1993

K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
Department of Pharmacy, Social Insurance Hazu Hospital, Mie-Ken, Japan.

We examined the effects of timing of administration of etoposide on cytosine arabinoside (ara-C) incorporation into DNA in L1210 ascites tumor. At 1 hr after injection of ara-C, 3-hr and 6-hr pretreatments with 15 mg/kg of etoposide increased ara-C incorporation to more than 200% as compared to that of ara-C given alone. Simultaneous administration of etoposide, however, decreased ara-C incorporation to 33% of that of ara-C alone. These results might explain the previously reported sequence dependency of the antitumor effect of etoposide and ara-C.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
January 1988, Medical oncology and tumor pharmacotherapy,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
December 1987, Cancer research,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
July 1984, Molecular pharmacology,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
September 1982, Cancer research,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
March 1988, Cancer research,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
April 1984, Cancer research,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
November 1985, Cancer research,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
November 1970, Cancer research,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
June 2000, FEBS letters,
K Ooi, and T Ohkubo, and H Kuwabara, and M Higashigawa, and H Kawasaki, and H Kakitoh, and Y Kagawa, and S Inagaki, and K Sumida, and M Sakurai
January 1982, Methods in enzymology,
Copied contents to your clipboard!